These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 30244638)

  • 1. Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients.
    Allison TA; Lin PJ; Gass JA; Chong K; Prater SJ; Escobar MA; Hartman HD
    J Intensive Care Med; 2020 Sep; 35(9):903-908. PubMed ID: 30244638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
    Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
    Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria.
    Dev P; Abousaab C; Zhou C; Sarode R
    J Thromb Thrombolysis; 2022 Feb; 53(2):249-256. PubMed ID: 34373984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
    Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
    Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors.
    Pon G; Pelsue B; Reddy ST; Parsha K; Zhang X; Gulbis B; Barreto A; Savitz SI; Escobar M; Allison TA
    Thromb Res; 2023 Sep; 229():46-52. PubMed ID: 37406569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
    Maragkos GA; Nelton EB; Richter S; Stippler M
    World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
    Grandhi R; Newman WC; Zhang X; Harrison G; Moran C; Okonkwo DO; Ducruet AF
    World Neurosurg; 2015 Dec; 84(6):1956-61. PubMed ID: 26341438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors.
    Hormese M; Littler A; Doane B; Glowacki N; Khimani A; Vivacqua N; Rudenberg K
    J Thromb Thrombolysis; 2021 Oct; 52(3):828-835. PubMed ID: 33725284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants.
    Dager WE; Roberts AJ; Nishijima DK
    Thromb Res; 2019 Jan; 173():71-76. PubMed ID: 30476716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
    Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
    Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.